JPWO2023288267A5 - - Google Patents

Info

Publication number
JPWO2023288267A5
JPWO2023288267A5 JP2024501757A JP2024501757A JPWO2023288267A5 JP WO2023288267 A5 JPWO2023288267 A5 JP WO2023288267A5 JP 2024501757 A JP2024501757 A JP 2024501757A JP 2024501757 A JP2024501757 A JP 2024501757A JP WO2023288267 A5 JPWO2023288267 A5 JP WO2023288267A5
Authority
JP
Japan
Prior art keywords
antigen
polypeptide
tcr
cancer
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525727A (ja
JP2024525727A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/073725 external-priority patent/WO2023288267A1/en
Publication of JP2024525727A publication Critical patent/JP2024525727A/ja
Publication of JPWO2023288267A5 publication Critical patent/JPWO2023288267A5/ja
Publication of JP2024525727A5 publication Critical patent/JP2024525727A5/ja
Pending legal-status Critical Current

Links

JP2024501757A 2021-07-14 2022-07-14 抗体由来の結合ドメインに融合した操作されたt細胞受容体 Pending JP2024525727A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221819P 2021-07-14 2021-07-14
US63/221,819 2021-07-14
PCT/US2022/073725 WO2023288267A1 (en) 2021-07-14 2022-07-14 Engineered t cell receptors fused to binding domains from antibodies

Publications (3)

Publication Number Publication Date
JP2024525727A JP2024525727A (ja) 2024-07-12
JPWO2023288267A5 true JPWO2023288267A5 (https=) 2025-07-23
JP2024525727A5 JP2024525727A5 (https=) 2025-07-23

Family

ID=83271692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501757A Pending JP2024525727A (ja) 2021-07-14 2022-07-14 抗体由来の結合ドメインに融合した操作されたt細胞受容体

Country Status (9)

Country Link
US (1) US20240342215A1 (https=)
EP (1) EP4370541A1 (https=)
JP (1) JP2024525727A (https=)
KR (1) KR20240034234A (https=)
CN (1) CN117980326A (https=)
AU (1) AU2022310862A1 (https=)
CA (1) CA3225252A1 (https=)
IL (1) IL309957A (https=)
WO (1) WO2023288267A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
US12421315B2 (en) 2019-05-08 2025-09-23 Regeneron Pharmaceuticals, Inc. CLL-1 targeted immunotherapies
AU2021244594A1 (en) * 2020-03-27 2022-12-01 Regeneron Pharmaceuticals, Inc. T cell receptors
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
WO2026078266A1 (en) * 2024-10-11 2026-04-16 Fundacion Para La Investigacion Medica Aplicada Bcma specific single domain antibodies (sdab), cars and other products derived therefrom, and their uses in therapy and diagnosis

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
NZ522840A (en) 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
ATE452972T1 (de) 2001-05-01 2010-01-15 Ca Nat Research Council Induzierbares expressionssystem in eukaryotischen zellen
AU2003210149B2 (en) 2002-01-03 2008-10-09 Bayer Schering Pharma Aktiengesellschaft Conjugates comprising an antibody specific for the ED-B domain of fibronectin and their use for the detection and treatment of tumours
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
DK1765860T3 (da) 2004-05-19 2009-03-09 Immunocore Ltd Ny-ESO-T.cellereceptor med höj affinitet
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
EP1934259A2 (en) 2005-10-11 2008-06-25 Ablynx N.V. Nanobodies and polypeptides against egfr and igf-ir
CA2651174A1 (en) 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
WO2008119566A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
EP2406284B9 (en) 2009-03-10 2017-03-01 Biogen MA Inc. Anti-bcma antibodies
ES2683695T3 (es) 2010-01-12 2018-09-27 The University Of North Carolina At Chapel Hill Repeticiones terminales invertidas restrictivas para vectores virales
CA2788682C (en) 2010-02-05 2019-03-05 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
JP6205363B2 (ja) 2011-09-26 2017-09-27 ジェイエヌ バイオサイエンシーズ エルエルシー ハイブリッド定常領域
US20150218280A1 (en) 2012-08-10 2015-08-06 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
CN104822705B (zh) 2012-10-24 2019-07-12 美国卫生和人力服务部 M971嵌合抗原受体
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
CN110511960B (zh) 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
ES2743809T3 (es) 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
CN107074970B (zh) 2014-08-04 2021-07-30 弗雷德哈钦森癌症研究中心 特异性针对wt-1的t细胞免疫疗法
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
EA036379B1 (ru) 2014-12-12 2020-11-02 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
JP2019525898A (ja) 2016-06-10 2019-09-12 ガデタ・ベー・フェー ヒト白血球抗原拘束ガンマデルタt細胞受容体及びその使用方法
EP3494138A1 (en) * 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP4282877A3 (en) 2016-08-10 2024-02-21 Legend Biotech Ireland Limited Chimeric antigen receptors targeting bcma and methods of use thereof
SG11201903400WA (en) 2016-10-17 2019-05-30 Pfizer Anti-edb antibodies and antibody-drug conjugates
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
AU2017382883B2 (en) 2016-12-21 2024-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技(香港)有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
US11236145B2 (en) 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
WO2018183888A2 (en) 2017-03-31 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
AU2018289428B2 (en) 2017-06-21 2024-06-27 The General Hospital Corporation Methods and compositions for chimeric antigen receptor targeting cancer cells
CA3080274A1 (en) 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
GB201717578D0 (en) 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor
CN112088008B (zh) 2018-01-11 2024-01-02 浙江煦顼技术有限公司 修饰细胞的扩增及其用途
CA3095920A1 (en) 2018-04-10 2019-10-17 Amgen Inc. Chimeric receptors to dll3 and methods of use thereof
JP2021527409A (ja) 2018-06-14 2021-10-14 ブルーバード バイオ, インコーポレイテッド Cd79aキメラ抗原受容体
EP3806857A4 (en) 2018-06-14 2022-03-02 2seventy bio, Inc. CD79A CHIMERIC ANTIGEN RECEPTORS
US20210393692A1 (en) 2018-11-13 2021-12-23 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy for cancer
US12291560B2 (en) 2018-12-14 2025-05-06 Regeneron Pharmaceuticals, Inc. Dimerizing agent regulated immunoreceptor complexes
CA3126422A1 (en) * 2019-01-14 2020-07-23 Nanjing Legend Biotech Co., Ltd. Chimeric receptor polypeptides and uses thereof
EP3714941A1 (en) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
CN114040927A (zh) 2019-05-04 2022-02-11 印希比股份有限公司 结合cd33的多肽及其用途
KR20220004751A (ko) 2019-05-04 2022-01-11 인히브릭스, 인크. CLEC12a 결합 폴리펩타이드 및 이의 용도
JP2022532868A (ja) 2019-05-04 2022-07-20 インヒブルクス インコーポレイテッド Cd123結合性ポリペプチド及びその使用
MX2022000896A (es) * 2019-07-24 2022-02-14 Regeneron Pharma Receptores de antigenos quimericos con especificidad por mage-a4 y usos de los mismos.
AU2021244594A1 (en) 2020-03-27 2022-12-01 Regeneron Pharmaceuticals, Inc. T cell receptors
US20230310604A1 (en) 2020-08-25 2023-10-05 2Seventy Bio, Inc. Bcma chimeric antigen receptors

Similar Documents

Publication Publication Date Title
Chen et al. Bispecific antibodies in cancer immunotherapy
US20240342283A1 (en) ROR1 CAR or ROR1 / CD19 Dual CAR T Cells for the Treatment of Tumors
US20230028399A1 (en) Bcma-directed cellular immunotherapy compositions and methods
RU2019126655A (ru) Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль
NZ720520A (en) Tagged chimeric effector molecules and receptors thereof
JP2018521628A5 (https=)
JP2015527070A5 (https=)
CN115279792B (zh) 对bcma特异的抗体及嵌合抗原受体
JP2020535796A5 (https=)
CN115698088A (zh) 免疫细胞衔接器多特异性结合蛋白及其制备和应用
CN109789164A (zh) 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体
CN114539402B (zh) 靶向Claudin18.2的抗体及其用途
IL301995A (en) Cells comprising t cell-antigen couplers and uses thereof
Hayashi et al. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells
JP2019505545A5 (https=)
JP2024105603A (ja) CARライブラリおよびscFvの製造方法
JPWO2023288267A5 (https=)
JPWO2020123938A5 (https=)
US20260055201A1 (en) Bispecific antibody and use thereof
JPWO2022170280A5 (https=)
JPWO2020092467A5 (https=)
JPWO2023044453A5 (https=)
JPWO2021211948A5 (https=)
CA3211519A1 (en) Anti-egfr single domain antibodies and therapeutic constructs
JPWO2021170100A5 (https=)